Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion

Low dose naltrexone (LDN) has been promising as a complementary medication for patients with a broad range of medical disorders. Although not a proven cure, evidence from clinical trials supports LDN as being a valuable adjunct for disorders in which the immune system plays a centralized role. Addit...

Descripción completa

Detalles Bibliográficos
Autores principales: Miskoff, Jeffrey A, Chaudhri, Moiuz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2018
Materias:
Family/General Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126779/
https://www.ncbi.nlm.nih.gov/pubmed/30197847
http://dx.doi.org/10.7759/cureus.2924
_version_ 1783353368001904640
author Miskoff, Jeffrey A
Chaudhri, Moiuz
author_facet Miskoff, Jeffrey A
Chaudhri, Moiuz
author_sort Miskoff, Jeffrey A
collection PubMed
description Low dose naltrexone (LDN) has been promising as a complementary medication for patients with a broad range of medical disorders. Although not a proven cure, evidence from clinical trials supports LDN as being a valuable adjunct for disorders in which the immune system plays a centralized role. Additionally, clinical trials have proposed a unique mechanism(s) allowing LDN to affect tumors including non-small cell lung cancer (NSCLC) at the cellular level by augmenting the immune system. We present a case of a 50-year-old male with a prolonged survival and a past medical history of prostate and lung cancer.
format Online
Article
Text
id pubmed-6126779
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-61267792018-09-07 Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion Miskoff, Jeffrey A Chaudhri, Moiuz Cureus Family/General Practice Low dose naltrexone (LDN) has been promising as a complementary medication for patients with a broad range of medical disorders. Although not a proven cure, evidence from clinical trials supports LDN as being a valuable adjunct for disorders in which the immune system plays a centralized role. Additionally, clinical trials have proposed a unique mechanism(s) allowing LDN to affect tumors including non-small cell lung cancer (NSCLC) at the cellular level by augmenting the immune system. We present a case of a 50-year-old male with a prolonged survival and a past medical history of prostate and lung cancer. Cureus 2018-07-05 /pmc/articles/PMC6126779/ /pubmed/30197847 http://dx.doi.org/10.7759/cureus.2924 Text en Copyright © 2018, Miskoff et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Family/General Practice
Miskoff, Jeffrey A
Chaudhri, Moiuz
Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion
title Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion
title_full Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion
title_fullStr Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion
title_full_unstemmed Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion
title_short Low Dose Naltrexone and Lung Cancer: A Case Report and Discussion
title_sort low dose naltrexone and lung cancer: a case report and discussion
topic Family/General Practice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126779/
https://www.ncbi.nlm.nih.gov/pubmed/30197847
http://dx.doi.org/10.7759/cureus.2924
work_keys_str_mv AT miskoffjeffreya lowdosenaltrexoneandlungcanceracasereportanddiscussion
AT chaudhrimoiuz lowdosenaltrexoneandlungcanceracasereportanddiscussion

Ejemplares similares